bambermycin concentrate- bambermycins powder
biovet joint stock company - bambermycins (unii: pp922a42v2) (bambermycins - unii:pp922a42v2) -
gainpro 10- bambermycins powder
huvepharma, inc. - bambermycins (unii: pp922a42v2) (bambermycins - unii:pp922a42v2) - bambermycins 22 g in 1 kg - indications for use: for increased rate of weight gain and improved feed efficiency in growing beef steers and heifers fed in confinement for slaughter. for increased rate of weight gain in growing beef steers and heifers on pasture (stocker, feeder, and slaughter), and replacement beef and dairy heifers on pasture. mixing directions and indications for use on reverse side. for use in manufactured feeds only. user safety warning: not for human use. keep out of reach of children. restricted drug (california) – use only as directed growing beef steers and heifers fed in confinement for slaughter: **the approved dose in growing beef steers and heifers fed in confinement for slaughter is 10 to 20 mg of bambermycins/hd/day. the amount of bambermycins will range between 1 and 4 grams per ton of feed depending upon the daily feed consumption of the cattle. the amount of type a medicated article added to the complete ration (type c medicated feed) must be based on daily feed consumption, the number of a
flavomycin type a medicated article- bambermycins powder
huvepharma, inc. - bambermycins (unii: pp922a42v2) (bambermycins - unii:pp922a42v2) - bambermycins 8.8 g in 1 kg - for increased rate of weight gain and improved feed efficiency in broiler chickens, growing-finishing swine and growing turkeys. for use in manufactured feeds only user safety warnings not for human use keep out of reach of children. restricted drug (california) – use only as directed net weight – 50 pounds (22.68 kg)
bambermycin 8%
international animal health products pty ltd - bambermycin - unknown - bambermycin ab active 0.0 - active constituent
bambermycin 4%
international animal health products pty ltd - bambermycin - unknown - bambermycin ab active 0.0 - active constituent
flavomycin 40
agrihealth nz limited - bambermycins - bambermycins 40 g/kg - antibiotic
flavomycin 4 antibiotic premix drug premix
huvepharma eood - bambermycin - drug premix - 4g - bambermycin 4g - poultry; poultry
flaveco 40 feed supplement
international animal health products pty ltd - flavophospholipol - oral powder, pre-mix - flavophospholipol antibiotic active 40.0 g/kg - nutrition & metabolism - calf | cattle | pig - piglet | pigs | poultry broilers (meat for human consum) | poultry layers (eggs for human consump) | turke - feed supplement | improve digestive efficacy | increase egg production | productivity improvements | promote animal growth | digestive aid | feed conversion | feed conversion efficacy | finishing | growth promotion | growth rate | improving feed efficiency | increasing rate of weight gain | liveweight gain
bleomycin pfi
megapharm ltd - bleomycin sulfate - powder for solution for injection - bleomycin sulfate 15000 iu/vial - bleomycin - bleomycin - bleomycin is useful in the management of the following neoplasms: squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. well differentiated tumors usually respond better than anaplastic ones.hodgkin's disease and other malignant lymphomas, including mycosis fungoides. testicular carcinoma (seminoma and no seminoma) .malignant effusions of serous cavities (intrapleural and intraperitoneal).secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. local treatment of refractory warts. bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy.
bleomycin injection, powder, lyophilized, for solution
hospira, inc. - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin 30 [usp'u] - bleomycin for injection should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin is poorer in patients with previously irradiated head and neck cancer. lymphomas hodgkin's disease, non-hodgkin's lymphoma. testicular carcinoma embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin has also been shown to be useful in the management of: malignant pleural effusion bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin for injection is contraindicated in patients who have demonstrated a hypersensitive or an idiosyncratic reaction to it.